Renaissance Technologies’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
Renaissance Technologies's ANTX Position: Q3 2026 in Review
Renaissance Technologies reduced its AN2 Therapeutics (ANTX) stake by 38% in Q3 2026, selling an estimated $263K and leaving 80,100 shares worth $426K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.
Renaissance Technologies first reported a position in ANTX in Q2 2022 and has held it in 12 quarters since. The position peaked at $800K in Q4 2024. 84 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- Renaissance Technologies held 80,100 shares of AN2 Therapeutics worth $426K as of Q3 2026.
- Renaissance Technologies sold 49,600 AN2 Therapeutics shares in Q3 2026, an estimated $263K.
- AN2 Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2678 holding.
- Renaissance Technologies first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 12 quarters since.
- Renaissance Technologies's AN2 Therapeutics position peaked at $800K in Q4 2024.
- 84 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.